Abidjan

Researchers are conducting an international observational study to understand acute infectious diseases in adults hospitalized with suspected or confirmed infections. This study aims to collect data and biospecimens from patients worldwide to characterize respiratory and non-respiratory infections, established infectious diseases, and emerging infectious diseases. The information gathered will help identify risk factors, clinical features, and management strategies, and guide future clinical trials. Participants in this study are adults admitted to a hospital with an acute infection or suspected infection. There is no intervention or treatment given as part of the study since it is observational. The study focuses on collecting clinical data and biospecimens during hospitalization to better understand the disease processes and outcomes. During the study, participants will be monitored for clinical outcomes such as mortality at 28 days, time to recovery, clinical improvement, organ support requirements, and organ failure scores. Data collection includes clinical assessments and biospecimen sampling. The study will continue until June 2027, with participants followed for outcomes mainly up to 28 days after enrollment. This observational approach supports the development of future clinical trials by providing detailed insights into acute infections.

Researchers are evaluating the clinical performance of the MagIA H3S, an In-Vitro Diagnostics Medical Device designed to detect multiple infections including HIV, Hepatitis B, Hepatitis C, and Syphilis. This observational study focuses on samples collected both prospectively and retrospectively from individuals in Ivory Coast and Kenya. The aim is to assess how well this multiplex point-of-care test identifies these infections in various populations. The study uses serum or plasma samples from different groups, including those with positive results for HIV-1, HIV-2, HCV, Hepatitis B surface antigen, or syphilis antibodies, as well as negative samples from blood donors, hospitalized patients, and vulnerable populations like drug users and prisoners. Additionally, negative samples containing potential interfering substances, such as samples from pregnant women or individuals with other infections or high levels of certain blood components, are also included to evaluate the tests accuracy in complex cases. Participants provide informed consent, and their samples undergo testing to measure the devices ability to detect antibodies or antigens related to these infections. The main outcomes include evaluating the performance of MagIA H3S in detecting HIV, Hepatitis B and C, and syphilis antibodies, as well as assessing cross-reactivity with other substances or co-infections. The study will monitor these outcomes at baseline using the collected serum or plasma samples, with no direct intervention or treatment involved.

Researchers are evaluating doravirine as an alternative to dolutegravir in people newly diagnosed with HIV-1 infection who have not yet received treatment. This Phase III, open-label, randomized clinical trial aims to determine if doravirine combined with tenofovir and lamivudine is not less effective than dolutegravir combined with tenofovir and lamivudine or emtricitabine. The study will be conducted across multiple countries including Brazil, Cameroon, Cte dIvoire, France, Mozambique, and Thailand, enrolling 610 participants. Participants will be randomly assigned to one of two groups one receiving doravirine 100 mg plus tenofovir DF 300 mg and lamivudine 300 mg daily, and the other receiving dolutegravir 50 mg plus tenofovir DF 300 mg and either lamivudine or emtricitabine daily. The treatment period will last for 96 weeks after starting antiretroviral therapy ART, with primary assessment at week 48 to measure viral suppression. During the study, participants will undergo evaluations to monitor viral load, drug resistance, metabolic health, body weight changes, liver and kidney function, cardiovascular status, and mental health. Adherence to ART will be tracked, and blood samples will be taken to measure drug levels and immune cell counts. The research team will review virological efficacy and safety outcomes at weeks 48 and 96, supporting a comprehensive understanding of the treatments effects over nearly two years of participation.

This registry collects detailed information about children diagnosed with cancer who are treated in pediatric oncology units affiliated with the French African Oncology Group in French-speaking Africa. Its goal is to gather data on patient numbers, cancer stage, treatments received, and outcomes to support better planning and delivery of pediatric oncology care in the region. The registry aims to provide valuable insights for local and national health authorities to improve pediatric cancer programs. Children and adolescents under 18 years old who present at participating pediatric oncology units and have any type of cancer are included in this observational registry. Data collected includes demographic information, socioeconomic status, clinical details, treatment status, vital status, treatment abandonment, and loss to follow-up. The information is entered online using the REDCap system and securely stored by the IT department at Gustave ROUSSY in Paris. Participants information is gathered continuously during their treatment and follow-up at the hospital units. The main measures tracked include the number of children suspected of having cancer within 12-month periods, their vital status, illness status, and treatment status. This ongoing data collection helps monitor outcomes and supports healthcare planning. Participation involves no experimental treatment and is focused on data recording and observation over time.

This research aims to collect real-world data on the characteristics, management, healthcare use, and outcomes of patients living with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It is an international observational registry that includes patients from many countries to better understand how these conditions are treated in everyday clinical practice. Participants in this registry are observed without receiving experimental treatments. Data are collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry includes groups of patients with type 2 diabetes, hypertension, chronic kidney disease, or heart failure, either as their primary condition or as a coexisting condition. Patients provide information about their health status, treatments, and outcomes over time. Researchers collect data on demographics, disease characteristics, laboratory tests, treatments, healthcare visits, hospitalizations, and lifestyle factors. The study measures many outcomes such as blood sugar levels, kidney function, heart function, medication use, and health events over an average of three years. Participation is voluntary and ongoing, with data collection continuing until the study end date in 2030.

Cervical cancer is a major health issue worldwide, especially in sub-Saharan Africa, where it is the leading cancer among women. Vaccination against human papillomavirus HPV helps prevent cervical cancer and is usually given to children aged 9 to 15 years. This research evaluates how combining HPV vaccination with adolescent primary care and preventive health services affects vaccine uptake and other health services in Cte dIvoire. The study aims to make service delivery more convenient and effective for adolescents in schools, communities, and health facilities. The study compares an intervention group receiving an optimized integrated adolescent health service package, including HPV vaccination, with a comparison group receiving routine adolescent health services. The intervention includes expanded availability of services through schools, communities, and health facilities, as well as community awareness activities. The comparison group receives the standard Systematic Medical Visit program for adolescents. The research uses a quasi-experimental design with data collected over time in two regions, each with intervention and comparison districts. Participants will be adolescents aged 9 to 15 and their parents or caregivers living in the study regions. The study involves surveys of households, parents, and adolescents at the beginning and end of the study, as well as interviews with program managers and community members. Researchers will measure HPV vaccination rates, intentions to vaccinate, knowledge about HPV, and attitudes towards integrated services. Service coverage data will be collected monthly during the intervention. The study will assess the feasibility, acceptability, effectiveness, and sustainability of the integrated adolescent health package over several months.

Researchers are conducting a phase III randomized controlled trial called INTENSE-TBM to evaluate treatments aimed at reducing death rates in adolescents and adults with tuberculous meningitis, including those with or without HIV infection in sub-Saharan Africa. The trial compares intensified tuberculosis meningitis treatment using high-dose rifampicin and linezolid against the World Health Organizations standard treatment, and also examines the effects of aspirin compared to a placebo. This study is carried out across multiple countries including Cte dIvoire, Madagascar, Uganda, and South Africa. Participants are randomly assigned to one of four groups standard WHO tuberculosis meningitis treatment with aspirin placebo, standard treatment with aspirin, intensified treatment with aspirin placebo, or intensified treatment with aspirin. The intensified treatment includes high doses of rifampicin and linezolid for the first eight weeks, followed by standard doses of rifampicin and isoniazid until week 40. Aspirin or placebo is taken daily during the first eight weeks. After week 8, all participants continue with standard treatment until week 40. During the 40-week follow-up, participants undergo regular assessments to monitor survival, neurological events, adverse effects, and disability. Laboratory tests, including culture and drug resistance evaluations, as well as pharmacokinetic studies in subsets of patients, are conducted. HIV-infected participants will have additional monitoring of AIDS-related illnesses, viral load, and immune cell counts. The primary outcome measures the rate of death from any cause up to 40 weeks, with secondary outcomes assessing safety, effectiveness, and quality of life related factors.

Researchers are evaluating different ways to deliver arpraziquantel, a child-friendly form of praziquantel, to preschool-aged children 2 to under 5 years who are usually missed in schistosomiasis treatment campaigns. This small-scale public health study is being conducted in Cte dIvoire, Kenya, and Uganda to understand how well these delivery platforms work in reaching children and to identify training and social mobilization needs for effective distribution. The study involves giving a single oral dose of arpraziquantel dispersible tablets at 50mgkg or 60mgkg depending on the country, to children in selected villages. Two main delivery platforms are used routine schistosomiasis mass drug administration campaigns led by national neglected tropical disease programs and vitamin A distribution or child health days led by nutrition programs. The study collects data before, during, and after drug distribution to assess coverage, feasibility, and acceptability of these delivery methods. Participants and caregivers will be involved in assessments before and after drug administration to capture training and social mobilization activities and to evaluate experiences of children, parents, community members, health workers, and program staff. Safety data including adverse events are collected using existing pharmacovigilance tools. The main outcome measured is how well the platforms perform for drug distribution, with additional evaluation of communication and training effectiveness. Data collection spans from three months before to twelve weeks after the drug distribution to inform future scale-up.

Researchers are evaluating how well different anti-malarial drugs work and how safe they are for treating uncomplicated Plasmodium falciparum malaria in adults, adolescents, and children. This study focuses on the parasite-killing effects and potential cure rates of these drugs when given alone or combined with others. It also looks at how the drugs are processed by the body to help decide doses for future studies. Participants will receive one of several treatments, including varying doses of the oral drug INE963, combinations of oral KAE609 Cipargamin with INE963 or KLU156, or the standard of care drug Coartem. The study has multiple parts with patients allocated randomly to different treatment groups. Dosing levels and combinations are tested to compare how effectively they clear the malaria parasite. During the study, participants will have their parasite levels monitored up to 7 days and clinical response assessed by day 29. Blood samples will be taken by day 22 to study drug levels and how the body absorbs and clears the medicines. Safety is monitored through reports of side effects until day 43. The total participation lasts through these assessments to understand treatment impact and tolerability.

Researchers are evaluating new treatment recommendations for children with Acute Lymphoblastic Leukemia ALL through the GFAOP group. This observational study aims to improve outcomes by applying precise protocols and logistical support in developing countries. The study includes both standard and high-risk ALL forms, focusing on achieving high remission rates and long-term survival. The treatment approach proposes anthracycline induction for high-risk cases, including children under 1 year or over 10 years, and uses Endoxan and high-dose Methotrexate in consolidation phases. The study also follows previously established protocols for standard risk patients, aiming to refine and confirm effective treatment strategies for children with ALL. Participants will be monitored for treatment feasibility, adherence, remission rates after induction, and survival without relapse over five years. Assessments include checking correct application of therapy within five weeks and complete remission around day 34 to 42 post-induction. The study expects to evaluate outcomes initially after two years and fully by five years, ensuring comprehensive follow-up and data collection throughout the study period.